BiotechTube

Estradiol + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vulvovaginal Atrophy

Conditions

Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse

Trial Timeline

Sep 1, 2014 → Oct 1, 2015

NCT ID
NCT02253173

About Estradiol + Placebo

Estradiol + Placebo is a phase 3 stage product being developed by TherapeuticsMD for Vulvovaginal Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT02253173. Target conditions include Vulvovaginal Atrophy, Menopause, Dyspareunia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT02253173Phase 3Completed
NCT02449902Phase 2Completed

Competing Products

10 competing products in Vulvovaginal Atrophy

See all competitors
ProductCompanyStageHype Score
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
77
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
77
Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene VaginalNovo NordiskPhase 3
76
FluconazolePfizerPhase 3
76
Clotrimazole vaginal tablet + FluconazoleBayerApproved
82
SCY-078 + FluconazoleScynexisPhase 2
44
IbrexafungerpScynexisPhase 3
69
Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tabletScynexisPhase 3
69
IbrexafungerpScynexisPhase 1
25
Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB)Matinas BiopharmaPhase 2
44

Other Products from TherapeuticsMD

Progesterone + PlaceboPhase 3
69
Estradiol + Progesterone + PlaceboPhase 3
69
oral estradiol 1.0 mg + oral progesterone 100 mgPhase 3
69
Estradiol + placeboPhase 2
44
Segesterone Acetate and Ethinyl EstradiolPhase 1
25